EyeBrain Appoints Business Developer for Northern Europe
News Apr 25, 2011
EyeBrain, has announced the appointment of Savita Bernal as business developer for Northern Europe. She will be responsible for the development of commercial and scientific activities in the UK, Ireland and the Nordic countries.
This is the first of a number of appointments to cover all European regions. They will focus on making sure the EyeBrain offer meets the differing requirements of national health authorities in Europe.
EyeBrain recently announced the availability of its eye-tracking system, the Mobile Eye Brain Tracker (Mobile EBT), which offers the efficient early diagnosis of Parkinson-plus diseases.
The device, which is already CE market, has been available in France, Belgium and Luxembourg since June 2010, and is expected to be introduced to the UK and Irish markets in the first half of 2011, followed by the Nordic regions before the end of the year.
Bernal’s primary task will be to support the launch of the new medical device, which can standardize medical eye movement exploration, in Northern Europe.
Bernal (30) joins EyeBrain from Ernst & Young Advisory, where her most recent position was external consultant. Prior to this, she acted as senior consultant on the life sciences sector. She holds a PhD in Cognitive Neuroscience, an MSc in Cognitive Science, an MSc in Cellular and Molecular Biology, as well as a Masters Degree in Project Management from the HEC Business School.
“We are really pleased to welcome Savita on board as she has all the qualities needed to ensure EyeBrain’s success in Northern European markets,” said Serge Kinkingnehun, Founder, CEO and Scientific Director of EyeBrain. “She is not only able to communicate with neurologists and ophthalmologists through her high-level scientific knowledge, but also has extensive experience in managing the marketing aspects of business development.”
The Mobile EBT is a medical eye tracker for neurologists. It has proven its efficacy in helping diagnose and differentiate between the various Parkinson-plus syndromes, a difficult task due to the similarity of syndromes.
Unlike research eye trackers already on the market, the Mobile EBT provides a complete clinical solution, and produces a medical report presenting the automatically analyzed data.
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019